Amedisys, Inc. (NASDAQ:AMED – Get Free Report) saw a large decrease in short interest in the month of June. As of June 15th, there was short interest totalling 2,360,000 shares, a decrease of 8.2% from the May 31st total of 2,570,000 shares. Based on an average daily volume of 271,400 shares, the days-to-cover ratio is presently 8.7 days. Currently, 7.4% of the company’s shares are sold short.
Analyst Upgrades and Downgrades
AMED has been the subject of a number of research analyst reports. Royal Bank of Canada upped their price objective on shares of Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 25th. StockNews.com raised shares of Amedisys from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $101.00 price target on shares of Amedisys in a report on Thursday, April 25th. Finally, Raymond James reaffirmed a “market perform” rating on shares of Amedisys in a research report on Tuesday, March 26th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $100.67.
Check Out Our Latest Research Report on AMED
Amedisys Stock Performance
Amedisys (NASDAQ:AMED – Get Free Report) last issued its earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. The company had revenue of $571.41 million during the quarter, compared to the consensus estimate of $565.38 million. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.00 earnings per share. As a group, equities research analysts expect that Amedisys will post 4.57 earnings per share for the current fiscal year.
Institutional Trading of Amedisys
Hedge funds have recently made changes to their positions in the company. Banque Cantonale Vaudoise acquired a new stake in Amedisys during the 1st quarter valued at $60,000. Covestor Ltd grew its stake in shares of Amedisys by 134.2% during the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock valued at $72,000 after acquiring an additional 447 shares in the last quarter. Cetera Trust Company N.A purchased a new stake in shares of Amedisys during the fourth quarter worth about $215,000. CWM LLC lifted its stake in shares of Amedisys by 40.4% in the fourth quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock worth $250,000 after acquiring an additional 757 shares in the last quarter. Finally, Contravisory Investment Management Inc. purchased a new position in Amedisys in the fourth quarter valued at about $258,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.
About Amedisys
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
See Also
- Five stocks we like better than Amedisys
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- 3 Ways To Invest In Coffee, Other Than Drinking It
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Quiet Period Expirations Explained
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.